AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01289171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycolic acid
Description: Those who met the study criteria commenced once daily use of 15% glycolic acid lotion to the face and/or dorsal hands, with an increase to twice daily application as tolerated after two weeks of use.
Study NCT01677351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: 4 mcg.kg-1, 20 minutes before cataract surgery
Study NCT01677351 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03346057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Description: Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Sugammadex 2 mg/kg for reversal of moderate NMB. Moderate block is a level of NMB in which peripheral nerve stimulation elicits one to four muscle twitches.
Study NCT03346057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Description: Following administration of NMBA (Rocuronium or Vecuronium) to achieve deep NMB, participants received a single i.v. bolus of Sugammadex 4 mg/kg for reversal of deep NMB. Deep block is a level of NMB in which peripheral nerve stimulation elicits no muscle twitches and high-frequency muscle stimulation elicits minimal levels of muscle contraction.
Study NCT03346057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 16 mg/kg
Description: Following administration of NMBA (Rocuronium) to achieve deep NMB, participants received a single i.v. bolus of Sugammadex 16 mg/kg for reversal of deep NMB. Deep block is a level of NMB in which peripheral nerve stimulation elicits no muscle twitches and high-frequency muscle stimulation elicits minimal levels of muscle contraction.
Study NCT03346057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine + Glycopyrrolate
Description: Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Neostigmine (50 μg/kg; 5 mg maximum) and Glycopyrrolate (10 μg/kg; 1 mg maximum) for reversal of moderate NMB. Moderate block is a level of NMB in which peripheral nerve stimulation elicits one to four muscle twitches.
Study NCT03346057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: To achieve NMB, participants received steroidal NMBA Rocuronium Bromide administered via IV infusion and dosed according to participant body weight. NMBAs were concomitant medications used per label and at Investigator's discretion as an adjunct to general anesthesia.
Study NCT03346057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: To achieve NMB, participants received steroidal NMBA Rocuronium Bromide administered via IV infusion and dosed according to participant body weight. NMBAs were concomitant medications used per label and at Investigator's discretion as an adjunct to general anesthesia.
Study NCT03346057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vecuronium
Description: To achieve NMB, participants received steroidal NMBA Vecuronium Bromide administered via IV infusion and dosed according to participant body weight. NMBAs were concomitant medications used per label and at Investigator's discretion as an adjunct to general anesthesia.
Study NCT03346057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vecuronium
Description: To achieve NMB, participants received steroidal NMBA Vecuronium Bromide administered via IV infusion and dosed according to participant body weight. NMBAs were concomitant medications used per label and at Investigator's discretion as an adjunct to general anesthesia.
Study NCT01236651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meperidine
Description: administer 100mg meperidine i.v during the 1st stage of labor and calculate the duration of this stage of labor
Study NCT01236651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotaverine
Description: administer 40mg drotaverine i.v during the 1st stage of labor and calculate the duration of this stage of labor
Study NCT03328533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Phenylephrine variable infusion with a starting rate of 0.75 mcg/Kg/min.
Study NCT03328533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Norepinephrine bitartrate variable infusion with a starting rate of 0.1 mcg/Kg/min (equivalent to norepinephrine base of 0.05 mcg/Kg/min).
Study NCT03328533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg.
Study NCT03328533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg.
Study NCT02460666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai-Chi-Chih (TCC)
Study NCT02460666 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education and Wellness Classes (HEW)
Study NCT02479334 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fat challenge breakfast
Description: In this intervention, subjects are asked to consume 200 ml control drinks (non-energy flavored water). Following 10 min. beverage consumption, subjects will be given standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
Study NCT02479334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fat challenge breakfast+spices
Description: In this intervention, subjects are asked to consume 200 ml spices drinks (non-energy flavored water + spices extract). Following 10 min. beverage consumption, subjects will be given standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
Study NCT02479334 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate challenge breakfast
Description: In this intervention, subjects are asked to consume 200 ml control drinks (non-energy flavored water). Following 10 min. beverage consumption, subjects will be given standardized high carbohydrate breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 60:20:20
Study NCT02479334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate challenge breakfast+spices
Description: In this intervention, subjects are asked to consume 200 ml spices drinks (non-energy flavored water + spices extract). Following 10 min. beverage consumption, subjects will be given standardized high carbohydrate breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 60:20:20
Study NCT02896179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training group+VR
Description: The first group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System plus Virtual Reality scenario. During each session, the patients will practice 15 to 20 min of simulated floor walking with simulating of a real walking trail. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
Study NCT02896179 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GEO
Description: The second group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GE-O System. During each session, the patients will practice 15 to 20 min of simulated floor walking. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles
Study NCT01849484 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation according to indication with hippocampal sparing
Description: Performed with hippocampal sparing Meningioma-total dose up to 50.4 Gy (+ additional boost up to 59.4 Gy) Hypophyseal adenoma - total dose up to 50.4 Gy (+additional boost up to 54 Gy) SCLC (prophylactic cranial irradiation) - total dose up to 36.0 Gy
Study NCT01849484 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation according to indication without hippocampal protection
Description: Performed with hippocampal sparing Meningioma-total dose up to 50.4 Gy (+ additional boost up to 59.4 Gy) Hypophyseal adenoma - total dose up to 50.4 Gy (+additional boost up to 54 Gy) SCLC (prophylactic cranial irradiation) - total dose up to 36.0 Gy
Study NCT00683566 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electrostimulation
Description: Stimulate STN (at 0, 5, 10, 15, 20, 25, 30, 40, 70 and 130 Hz) in chronically implanted patients at rest and during simple and complex motor tasks
Study NCT03707925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cone-Beam Computed Tomography
Description: Undergo CBCT
Study NCT03707925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo standard resection
Study NCT03707925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Ablation
Description: Undergo bronchoscopic laser ablation
Study NCT00797498 — intervention group
Intervention type: OTHER
Intervention: Xerostomia questionnaire
Description: All of the tests, procedures and treatments may be considered standard of care for someone with this type of cancer, except for the Xerostomia Questionnaire.
Study NCT02750098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose measurement
Description: 1. Elective cataract surgery~2. Blood glucose measurement - glucometer~3. Aqueous humor glucose measurement - at beginning of cataract surgery - glucometer~4. Perioperative Hemoglobin A1c level - blood laboratory test
Study NCT00662779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arformoterol
Description: 15 mcg arformoterol nebulizer
Study NCT00662779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol
Description: Formoterol 12 mcg/inhalation, dry powder inhaler
Study NCT00662779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo dry powder capsules ( lactose) and placebo normal saline for nebulization
Study NCT02536573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radlink Surgical Positioning Software
Study NCT04896138 — intervention group
Intervention type: OTHER
Intervention: Interstitial Lung Disease
Description: Not applicable - this is not an interventional trial
Study NCT03553654 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: low dose CT
Description: CT-based protocol for detection of anthracycline-induced myocardial dysfunction at early stages
Study NCT01117857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: One-week placebo lead-in, followed by Duloxetine 30 mg per day for one week. After one week on 30 mg, the dosage will be increased 60 mg per day for the remaining 7 weeks of the study.
Study NCT02499081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Study NCT03773822 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hydrocortisone + Flucortac
Description: Low dose steroids
Study NCT03773822 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00321659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic
Description: 3x/week of walking and cycling
Study NCT00321659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training
Description: 3x/week of resistance training activities
Study NCT00321659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination
Description: 3x/week of aerobic and strength training activities
Study NCT00321659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FSHC
Description: Biweekly group education group meetings
Study NCT00364156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Patch Treatment
Description: 8-weeks of nicotine patch + 16-weeks of placebo
Study NCT00364156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 24-weeks of nicotine patch
Description: 24-weeks of 21mg nicotine patch
Study NCT03450720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2737 single dose
Description: GLPG2737 oral suspension, single dose
Study NCT03679806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Halliwick
Description: The exercise program was progressed by increasing the speed and the range of motion of the movements. Patients were asked not to accelerate the exercise and to focus on their alignment. Mental adjustment, sagittal rotation, transverse rotation, and combined rotation controls, balances in stillness steps of the Halliwick concept were included.
Study NCT03679806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic Plyometric Exercises
Description: The APE programme was progressed by increasing speed and the range of motion of the movements. Patients were carefully informed not to deform the exercise just to emulate the speed. The three phases of each exercise; eccentric (or loading) phase, the amortization phase, and the concentric (or unloading) phase explained thoroughly at the beginning of every exercise.
Study NCT01118689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: MLN0128 administered orally once daily for 28 days
Study NCT04452487 — intervention group
Intervention type: BEHAVIORAL
Intervention: decisions of limitations and stop processing
Description: Compliance of the modalities of decisions of limitations and stop processing
Study NCT02910479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-Celsius thermometer
Description: comparison of temperature between e-celsius and thermometer, rectal thermometer, esophageal thermometer, vital sense capsule thermometer
Study NCT02910479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rectal thermometer
Study NCT02910479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal thermometer
Study NCT02910479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vital sense capsule thermometer
Study NCT04641182 — intervention group
Intervention type: OTHER
Intervention: Prone position
Description: Prone position as indicated by the treating physician as specified in the institutional protocol
Study NCT03856788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 40 mL sterile normal saline
Study NCT03856788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 40 mL 0.25% bupivacaine
Study NCT03561805 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ECG monitoring
Description: Prolonged continuous ECG monitoring using the CardioSTAT® device within the 3 months prior to the TAVI procedure
Study NCT00106704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Sitagliptin
Description: sitagliptin 10 mg tablet, once daily for 54 weeks
Study NCT00106704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo oral tablet once daily for 24 weeks
Study NCT00106704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Pioglitazone
Description: Pioglitazone 30 mg tablet once daily for 30 weeks
Study NCT01403532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traditional intervention for HH using HCG and FSH
Description: Human chorionic gonadotropin(HCG),2000U,im,2 times/week, one year and a half; Follicle stimulating hormone(FSH),75U, im, 3 times/week, one year;
Study NCT01403532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential intervention for HH using HCG and FSH
Description: Human chorionic gonadotropin,2000U,im, 2 times/week, one and half a year Follicle stimulating hormone,75U,im,3 times/week, every other three months
Study NCT01403532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential intervention for HH using HCG and FSH plus zinc
Description: Human chorionic gonadotropin,2000U,im,2 times/week, one year and a half Follicle stimulating hormone,75U, im, 3 times/week, every other three months Zinc gluconate 20mg,P.O, twice daily
Study NCT03516630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone 20 mg
Description: Oral drops
Study NCT03516630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone 60 mg
Description: Oral drops
Study NCT03516630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone 140 mg
Description: Oral drops
Study NCT03516630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral drops
Study NCT02749656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% Desoximetasone cream (Topoxy®)
Description: apply on the scalp psoriasis lesion twice a day
Study NCT02749656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% Desoximetasone cream (Topicorte®)
Description: apply on the scalp psoriasis lesion twice a day
Study NCT02749656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: apply on the scalp psoriasis lesion twice a day
Study NCT01298518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04620110
Description: 5 mg of PF-04620110 given once daily
Study NCT01298518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04620110
Description: 2.5 mg of PF-04620110 given twice daily
Study NCT01298518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo giving for 4 weeks
Study NCT02089841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: Blood samples will be collected on blood slides and filter papers for asexual parasites assessment both by microscope and molecular genotyping respectively following treatment with artemether-lumefantrine, to assess its efficacy.
Study NCT03877432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermatome stimulation
Description: Dermatome (S2-S4) stimulation is aimed at improving the function of bladder storage and bladder capacity. A total of 8 serial cystometrograms will be performed: 2 control fills, followed by 4 fills with stimulation, followed by 2 control fills. The minimum (or threshold) stimulation amplitude (T) necessary to elicit the genito-anal reflex was first determined for each subject. Subsequently, each subject received a randomized sequence of cystometric fill trials with and without continuous dermatome stimulation. The dermatome stimulation was randomly stimulated at stimulation amplitudes of 1, 2, 3, and 4 T.
Study NCT01110811 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transoral Incisionless Fundoplication (TIF)
Description: The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degress around the esophagus.
Study NCT01110811 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transoral Incisionless Fundoplication (TIF)
Description: The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degress around the esophagus.
Study NCT02921204 — intervention group
Intervention type: OTHER
Intervention: Vitamin D status
Description: There is no intervention in this study
Study NCT04525482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early goal-directed sedation programs
Description: A. Provide sedation at the beginning of the titration of dextrometomidine; b. Optimize sedation when dextrometomidine is used alone and at a maximum dose not sufficient to provide comfort and safety to the patient and to achieve a level of sedation at any time specified by the treating physician. C. Provides immediate recovery and sedation, and can control sudden agitation at any time
Study NCT03456531 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed radiofrequency
Description: The patient will have pulsed radiofrequency to suprascapular nerve for 6 minutes
Study NCT03456531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NSAIDs ibubrofen,Aspirin
Description: medical treatment as NSAIDs ibubrofen,Aspirin
Study NCT03196232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Given PO
Study NCT03196232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02882932 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Super Oxidized Solution in group I
Description: Two groups were made as group I and group II. Peritoneal Lavage was given with SOS and normal saline in group I. in group II only normal saline wash was given.
Study NCT03543696 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single Dose Radiotherapy (SDRT)
Study NCT02927418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength & Conditioning
Study NCT02927418 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study NCT00506545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 619734
Description: SCH 619734 50-mg capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.
Study NCT00506545 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dose 1
Description: Matching placebo capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.